Regulatory Approval

With triple-digit loan volume growth and a landmark AAA rating, Figure Technology Solutions' latest results suggest tokenized assets are finally breaking through.

A new SEC-registered transfer agent, OpenAgent, launches to bridge blockchain efficiency with institutional compliance, heralding a new era for digital assets.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

A new online pharmacy is challenging the 'prescribe and forget' model for weight loss drugs, offering integrated clinical care to combat safety concerns.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Irish firm InVera Medical wins CE Mark for a new varicose vein device, promising a less invasive, office-based treatment for a widespread condition.

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

Hong Kong's Powell Max resolved a critical Nasdaq compliance issue, but a look at its finances and a second regulatory notice reveals greater challenges.

Global broker PU Prime gains a coveted CMA license, deepening its regulatory footprint and opening doors to the UAE's rapidly evolving financial landscape.

Finnish medtech firm Bioretec reports staggering 2025 losses but bets its future on breakthrough implant technology and a complete strategic overhaul.

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

A federal agency's safety warning has sparked a high-stakes legal fight, pitting a small business against regulators in a battle over science and survival.

FDA approval for new 6- and 24-count NARCAN packs aims to streamline distribution for first responders and public health groups on the front lines.

DifGen Pharmaceuticals' new FDA-approved generic eye drop is only the second of its kind, promising to increase competition and lower costs for patients.

In a landmark move, the FDA has removed major risk warnings from hormone therapy drugs, signaling a new era for women's health after decades of fear.

F/m Investments just launched a fund that's both an ETF and a mutual fund. Here's why this regulatory first is a game-changer for the entire industry.

Workers' compensation specialist Summit enters Delaware and Pennsylvania, promising tailored services and shaking up the market for local businesses.

NanaWall's MultiSlide 630 meets Florida's tough codes, blending expansive design with the critical safety and resilience architects need in coastal regions.

An Ohio company is using nanotechnology to create high-performance packaging that disappears, tackling the global crisis of microplastic waste at its source.

A new deal for a massive compressed air energy storage plant in California aims to solve grid woes and meet the surging power demands of AI.